SANTA CLARA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business ...
Luminex Corporation (NASDAQ: LMNX) today announced a definitive agreement to acquire privately-held, GenturaDx, a molecular diagnostics company focused on making nucleic acid testing both affordable ...
Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical ...
Get to know Luminex’s xMAP® Technology all over again. For 27 years, xMAP Technology has become known as the worldwide leader in bead-based multiplexing. With the new xMAP INTELLIFLEX®, we have ...
Luminex Corporation has announced the global launch of MAGPIX®, an analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under ...
Luminex has developed multiple cassettes and assays for ARIES®, the company’s real-time PCR-based molecular diagnostics platform. Cassettes contain extraction, purification, amplification, and ...
"As the worldwide leader in multiplexing solutions, our goal at Luminex is to develop innovative and effective products that meet a range of laboratories' needs," said Patrick J. Balthrop, president ...
Luminex Corporation, Austin, Texas, is being awarded an $11,640,787 cost-plus-fixed-fee contract for development of a flexible and highly portable diagnostic instrument that will be capable of rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results